telbivudine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
uridine derivatives used as antiviral agents and as antineoplastics 4220 3424-98-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sebivo
  • telbivudine
  • beta-L-Thymidine
  • epavudine
  • L-Thymidine
A thymidine derivative and antiviral agent that inhibits DNA synthesis by HEPATITIS B VIRUS and is used for the treatment of CHRONIC HEPATITIS B.
  • Molecular weight: 242.23
  • Formula: C10H14N2O5
  • CLOGP: -1.38
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 99.10
  • ALOGS: -0.56
  • ROTB: 2
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 68 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility) 66.80 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma) 1 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.177 Moderate 0.72
caco2-efflux Caco-2 efflux ratio (BA/AB) 5.284 Moderate 0.72
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 2.046 10^-6 cm/s Moderate 0.72
dh-clint Dog hepatocyte intrinsic clearance 1.897 uL/min/10^6 cells Moderate 0.72
dppb Dog plasma protein binding (% unbound) 93.160 % Moderate 0.72
fcs-ppb Fetal calf serum protein binding (% unbound) 93.110 % Moderate 0.72
herg hERG pIC50 3.623 pIC50 Moderate 0.72
hh-clint Human hepatocyte intrinsic clearance 1.199 uL/min/10^6 cells Moderate 0.72
hlm-clint Human liver microsomal intrinsic clearance 3.069 uL/min/mg protein Moderate 0.72
hppb Human plasma protein binding (% unbound) 92.140 % Moderate 0.72
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,ITK,MAP3K21,MAPK7,NTRK2,PDK1,PDK2,PRKDC,SIK2,TEK 21
kinase-selectivity-class GRK2,MAP2K6 2
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.208 Moderate 0.72
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.429 Moderate 0.72
mh-clint Mouse hepatocyte intrinsic clearance 0.276 Moderate 0.72
mppb Mouse plasma protein binding (% unbound) 95.410 Moderate 0.72
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.495 Moderate 0.72
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1
pppb Pig plasma protein binding (% unbound) 95.500 % Moderate 0.72
rat-kpuu-brain Rat brain Kpuu 0.049 % Moderate 0.72
rh-clint Rat hepatocyte intrinsic clearance 0.995 uL/min/10^6 cells Moderate 0.72
rh-fuinc Rat hepatocyte fraction unbound in incubation 94.410 % Moderate 0.72
rppb Rat plasma protein binding (% unbound) 93.680 % Moderate 0.72
solubility-dd Solubility at pH 7.4 in DMSO 937.562 uM Moderate 0.72

Approvals:

DateAgencyCompanyOrphan
April 24, 2007 EMA
Oct. 25, 2006 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug resistance 97.95 91.74 20 154 30429 90597844

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood creatine phosphokinase increased 157.64 75.49 50 679 48288 42572318
Drug resistance 117.90 75.49 37 692 34211 42586395
Hepatitis B DNA increased 94.75 75.49 15 714 574 42620032
Pathogen resistance 87.17 75.49 23 706 11427 42609179
Myalgia 87.13 75.49 39 690 96041 42524565

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood creatine phosphokinase increased 214.53 65.07 57 714 73020 110515508
Pathogen resistance 130.05 65.07 29 742 17643 110570885
Drug resistance 123.31 65.07 35 736 56339 110532189
Viral mutation identified 122.91 65.07 22 749 4397 110584131
Hepatitis B DNA increased 110.50 65.07 16 755 839 110587689
Myalgia 95.86 65.07 41 730 222340 110366188

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AF11 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleoside and nucleotide reverse transcriptase inhibitors
FDA MoA N0000009947 Nucleoside Reverse Transcriptase Inhibitors
FDA EXT N0000175459 Nucleoside Analog
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
FDA EPC N0000175656 Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:36044 antiviral drug
CHEBI has role CHEBI:59897 EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
CHEBI has role CHEBI:62868 hepatoprotective agent
CHEBI has role CHEBI:64951 anti-HBV agent

Related Drugs by ATC class:

J05AF Nucleoside and nucleotide reverse transcriptase inhibitors 12 drugs
abacaviradefovir dipivoxilclevudinedidanosineemtricitabineentecavirlamivudinestavudinetenofovir alafenamidetenofovir disoproxilzalcitabinezidovudine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic type B viral hepatitis indication 61977001
Myositis contraindication 26889001 DOID:633
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Disorder of muscle contraindication 129565002 DOID:423
Steatosis of liver contraindication 197321007
Peripheral nerve disease contraindication 302226006
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.46 acidic
pKa2 13.02 acidic
pKa3 13.7 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Protein P Polyprotein INHIBITOR EC50 5.89 DRUG LABEL DRUG LABEL
Capsid protein Structural EC50 6.09 CHEMBL

External reference:

IDSource
4025782 VUID
N0000179779 NUI
D06675 KEGG_DRUG
4025782 VANDF
C1453933 UMLSCUI
CHEBI:63624 CHEBI
LLT PDB_CHEM_ID
CHEMBL374731 ChEMBL_ID
D000077712 MESH_DESCRIPTOR_UI
DB01265 DRUGBANK_ID
8296 INN_ID
2OC4HKD3SF UNII
159269 PUBCHEM_CID
474128 RXNORM
22372 MMSL
d05912 MMSL
011809 NDDF
424071004 SNOMEDCT_US
425347005 SNOMEDCT_US
2OC4HKD3SF INXIGHT DRUGS

Pharmaceutical products:

None